A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen |
| |
| Authors: | Ma Xiao-Jun Wang Zuncai Ryan Paula D Isakoff Steven J Barmettler Anne Fuller Andrew Muir Beth Mohapatra Gayatry Salunga Ranelle Tuggle J Todd Tran Yen Tran Diem Tassin Ana Amon Paul Wang Wilson Wang Wei Enright Edward Stecker Kimberly Estepa-Sabal Eden Smith Barbara Younger Jerry Balis Ulysses Michaelson James Bhan Atul Habin Karleen Baer Thomas M Brugge Joan Haber Daniel A Erlander Mark G Sgroi Dennis C |
| |
| Affiliation: | Arcturus Bioscience, Inc., 2715 Loker Avenue West, Carlsbad, CA 92008, USA. |
| |
| Abstract: | Tamoxifen significantly reduces tumor recurrence in certain patients with early-stage estrogen receptor-positive breast cancer, but markers predictive of treatment failure have not been identified. Here, we generated gene expression profiles of hormone receptor-positive primary breast cancers in a set of 60 patients treated with adjuvant tamoxifen monotherapy. An expression signature predictive of disease-free survival was reduced to a two-gene ratio, HOXB13 versus IL17BR, which outperformed existing biomarkers. Ectopic expression of HOXB13 in MCF10A breast epithelial cells enhances motility and invasion in vitro, and its expression is increased in both preinvasive and invasive primary breast cancer. The HOXB13:IL17BR expression ratio may be useful for identifying patients appropriate for alternative therapeutic regimens in early-stage breast cancer. |
| |
| Keywords: | |
| 本文献已被 PubMed 等数据库收录！ |
|
